Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11146160rdf:typepubmed:Citationlld:pubmed
pubmed-article:11146160lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:11146160lifeskim:mentionsumls-concept:C0079459lld:lifeskim
pubmed-article:11146160lifeskim:mentionsumls-concept:C0001617lld:lifeskim
pubmed-article:11146160lifeskim:mentionsumls-concept:C0034809lld:lifeskim
pubmed-article:11146160lifeskim:mentionsumls-concept:C0237284lld:lifeskim
pubmed-article:11146160lifeskim:mentionsumls-concept:C1853118lld:lifeskim
pubmed-article:11146160lifeskim:mentionsumls-concept:C1710082lld:lifeskim
pubmed-article:11146160lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:11146160lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:11146160pubmed:issue12lld:pubmed
pubmed-article:11146160pubmed:dateCreated2001-1-10lld:pubmed
pubmed-article:11146160pubmed:abstractTextMore than 90% of patients with severe congenital neutropenia (SCN) respond to granulocyte colony-stimulating factor (G-CSF) therapy. The basis for the refractory state in the remaining patients is unknown. To address this issue, we studied a child with SCN who was totally unresponsive to G-CSF and had a novel point mutation in the extracellular domain of the G-CSF receptor (GCSF-R). Marrow stromal support of granulopoiesis was evaluated by plating CD34(+) cells on preformed stromal layers. Nonadherent cells were harvested and assayed in clonogenic assays for granulocytic colony production. The in vitro effect of G-CSF and corticosteroids on granulopoiesis was evaluated in clonogenic assays of marrow mononuclear cells, by proliferation studies of the murine myeloid cell line 32D expressing the patient's mutated G-CSFR, and by measuring STAT5 activation in nuclear extracts from stimulated cells.Patient's stroma supported granulopoiesis derived from control marrow CD34(+) cells in a normal manner. Normal stroma, however, failed to induce granulopoiesis from patient's CD34(+) cells. Clonogenic assays of the patient's marrow mononuclear cells incorporating either G-CSF or hydrocortisone produced little neutrophil growth. In contrast, inclusion of both G-CSF and hydrocortisone in the cytokine "cocktail" markedly increased the neutrophil numbers. Proliferation of 32D cells expressing the mutated receptor and STAT5 activation were improved by a combination of G-CSF and dexamethasone. When small daily doses of oral prednisone were then administered to the patient with conventional doses of subcutaneous G-CSF, the patient responded with increased neutrophil numbers and with a complete reversal of the infectious problems. These data provide insight into SCN unresponsive to standard G-CSF treatment and to the potential corrective action of combined treatment with G-CSF and corticosteroids through synergistic activation of STAT5.lld:pubmed
pubmed-article:11146160pubmed:languageenglld:pubmed
pubmed-article:11146160pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:citationSubsetIMlld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11146160pubmed:statusMEDLINElld:pubmed
pubmed-article:11146160pubmed:monthDeclld:pubmed
pubmed-article:11146160pubmed:issn0301-472Xlld:pubmed
pubmed-article:11146160pubmed:authorpubmed-author:FreedmanM HMHlld:pubmed
pubmed-article:11146160pubmed:authorpubmed-author:WardA CAClld:pubmed
pubmed-article:11146160pubmed:authorpubmed-author:GaddK GKGlld:pubmed
pubmed-article:11146160pubmed:authorpubmed-author:SERFBBlld:pubmed
pubmed-article:11146160pubmed:issnTypePrintlld:pubmed
pubmed-article:11146160pubmed:volume28lld:pubmed
pubmed-article:11146160pubmed:ownerNLMlld:pubmed
pubmed-article:11146160pubmed:authorsCompleteYlld:pubmed
pubmed-article:11146160pubmed:pagination1381-9lld:pubmed
pubmed-article:11146160pubmed:dateRevised2009-11-3lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:meshHeadingpubmed-meshheading:11146160...lld:pubmed
pubmed-article:11146160pubmed:year2000lld:pubmed
pubmed-article:11146160pubmed:articleTitleCombined corticosteroid/granulocyte colony-stimulating factor (G-CSF) therapy in the treatment of severe congenital neutropenia unresponsive to G-CSF: Activated glucocorticoid receptors synergize with G-CSF signals.lld:pubmed
pubmed-article:11146160pubmed:affiliationDepartment of Pediatrics, Division of Hematology and Oncology and Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.lld:pubmed
pubmed-article:11146160pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11146160pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:11146160pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11146160lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11146160lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11146160lld:pubmed